Human Papillomavirus Infection Among Sexually Active Young Women in the United States: Implications for Developing a Vaccination Strategy

Objectives: Population-level data on prevalence and distribution of human papillomavirus (HPV) types in the United States are necessary to guide optimal vaccination strategies. Study: Urine specimens from 3262 women ages 18 to 25 in the National Longitudinal Study of Adolescent Health (Wave III) were tested and typed for HPV. Poststratification sampling weights generated nationally representative estimates. Results: Overall HPV prevalence was 26.9% and as high as 14.3% among women with 1 lifetime partner but did not vary by geographic region. High-risk types were detected in 20%; ∼10% were infected with types in current candidate vaccines. HPV infection was independently associated with mixing sex with alcohol, a black partner, >3 lifetime sex partners, being single, and illegal drug use. Having a current sex partner and receptive oral sex were inversely associated with HPV. Conclusion: HPV prevalence was high throughout the country, even among women with only 1 lifetime partner, suggesting early and widespread rather than targeted immunization of young women.

[1]  A. Shaw.  Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented? , 2005, Gynecologic oncology.

[2]  M. Handcock,et al.  The Prevalence of Trichomoniasis in Young Adults in the United States , 2005, Sexually transmitted diseases.

[3]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[4]  W. Reeves,et al.  Seroprevalence of human papillomavirus type 16 in children. , 2005, The Journal of infectious diseases.

[5]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[6]  P. Bearman,et al.  After the promise: the STD consequences of adolescent virginity pledges. , 2005, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[7]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[8]  K. Holmes,et al.  Influence of study population on the identification of risk factors for sexually transmitted diseases using a case-control design: the example of gonorrhea. , 2004, American journal of epidemiology.

[9]  S. Franceschi,et al.  Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. , 2004, The Journal of infectious diseases.

[10]  S. Ragot,et al.  Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security , 2004, Journal of medical virology.

[11]  William C Miller,et al.  Prevalence of chlamydial and gonococcal infections among young adults in the United States. , 2004, JAMA.

[12]  M. Hagensee,et al.  Optimization of PCR based detection of human papillomavirus DNA from urine specimens. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  S. Franceschi,et al.  Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study , 2004, British Journal of Cancer.

[14]  J. Gray,et al.  Detection and typing of human papillomavirus DNA in paired urine and cervical scrapes , 1999, European Journal of Epidemiology.

[15]  J. Papp,et al.  Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. , 2004, The Journal of infectious diseases.

[16]  I. Catalá,et al.  Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain , 2003, Sexually transmitted diseases.

[17]  N. Muñoz,et al.  Prevalence of Human Papillomavirus Infection Among Women in Concordia, Argentina:: A Population-Based Study , 2003, Sexually transmitted diseases.

[18]  P. Coursaget,et al.  Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. , 2003, The Journal of infectious diseases.

[19]  S. Franceschi,et al.  HUMAN PAPILLOMAVIRUS INFECTION AMONG WOMEN IN SOUTH AND NORTH VIETNAM , 2003 .

[20]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[21]  N. Kiviat,et al.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. , 2003, American journal of epidemiology.

[22]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[23]  W. Reeves,et al.  Seroprevalence of human papillomavirus type 16 infection in the United States. , 2002, The Journal of infectious diseases.

[24]  L. Koutsky,et al.  Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?: A Meta-Analysis , 2002, Sexually transmitted diseases.

[25]  B. Lloveras,et al.  Human papillomavirus genotypes in rural Mozambique , 2001, The Lancet.

[26]  C. Peyton,et al.  Determinants of genital human papillomavirus detection in a US population. , 2001, The Journal of infectious diseases.

[27]  K. Shah,et al.  Concordance of human papillomavirus in the cervix and urine among inner city adolescents , 2000, The Pediatric infectious disease journal.

[28]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[29]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[30]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[31]  L Beardsley,et al.  Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. , 1996, The Journal of infectious diseases.

[32]  J. Feldman,et al.  Declining Prevalence of Cervicovaginal Human Papillomavirus Infection With Age Is Independent of Other Risk Factors , 1996, Sexually transmitted diseases.

[33]  L. Brinton,et al.  Determinants of Genital Human Papillomavirus Infection in Low‐Income Women in Washington, D.C , 1993, Sexually transmitted diseases.

[34]  C. Wheeler,et al.  Determinants of Genital Human Papillomavirus Infection Among Cytologically Normal Women Attending the University of New Mexico Student Health Center , 1993, Sexually transmitted diseases.

[35]  David R. Scott,et al.  Determinants of Genital Human Papillomavirus Infection in Low‐Risk Women in Portland, Oregon , 1993, Sexually transmitted diseases.

[36]  B. Hansson,et al.  Human papillomavirus DNA in urine samples compared with that in simultaneously collected urethra and cervix samples , 1993, Journal of clinical microbiology.

[37]  A. Reingold,et al.  Genital human papillomavirus infection in female university students as determined by a PCR‐based method , 1991, JAMA.

[38]  Steven Wolinsky,et al.  The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses , 1989 .